Page last updated: 2024-12-08

1,4,7-triazacyclononane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,4,7-triazacyclononane, often abbreviated as **TACN**, is a cyclic organic compound with a nine-membered ring containing three nitrogen atoms.

**Structure and Properties:**

* **Structure:** It consists of a nine-membered ring with three nitrogen atoms at positions 1, 4, and 7, and six carbon atoms.
* **Properties:**
* **Basic:** The nitrogen atoms in TACN are basic, allowing it to coordinate with metal ions.
* **Rigid:** The cyclic structure provides rigidity, influencing the coordination geometry of the metal ion.
* **Solubility:** TACN is soluble in water and many organic solvents.

**Importance in Research:**

TACN is an important compound in research due to its ability to bind to metal ions, forming stable complexes. It has applications in various fields:

* **Catalysis:**
* TACN complexes can be used as catalysts in a wide range of reactions, including organic synthesis, oxidation, and reduction.
* The rigid structure and basicity of TACN contribute to the catalytic activity by providing specific coordination environments and promoting electron transfer.
* **Medicine:**
* TACN complexes can be used as diagnostic agents and therapeutic agents.
* For example, radiolabeled TACN complexes can be used for imaging, and some TACN complexes have shown promise in treating cancer.
* **Materials Science:**
* TACN complexes can be used to prepare new materials with unique properties, such as luminescence, magnetism, and conductivity.
* The ability of TACN to bind metal ions allows for the formation of metal-organic frameworks (MOFs) with diverse structures and applications.
* **Environmental Chemistry:**
* TACN can be used to remove heavy metals from water and soil, contributing to environmental remediation.
* The strong binding affinity of TACN for metal ions makes it a promising candidate for sequestering pollutants.

**Examples of Research:**

* **TACN-based catalysts:** TACN complexes have been used in the development of catalysts for various reactions, including the oxidation of alcohols, the reduction of nitro compounds, and the synthesis of polymers.
* **TACN-based radiopharmaceuticals:** Radiolabeled TACN complexes have been explored for imaging tumors and for targeted radiotherapy.
* **TACN-based MOFs:** TACN has been used as a building block in the construction of MOFs with potential applications in gas storage, catalysis, and separation.

**In summary, 1,4,7-triazacyclononane (TACN) is a versatile compound with numerous applications in research due to its ability to bind metal ions and form stable complexes. Its unique properties make it an important tool in catalysis, medicine, materials science, and environmental chemistry.**

1,4,7-triazacyclononane: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID188318
CHEMBL ID1650628
CHEBI ID37405
SCHEMBL ID132539
MeSH IDM0203920

Synonyms (36)

Synonym
4730-54-5
1,4,7-triazonane
BIDD:GT0562
NCI60_028927
tacn
1,4,7-triazacyclononane
CHEBI:37405 ,
[9]anen3
inchi=1/c6h15n3/c1-2-8-5-6-9-4-3-7-1/h7-9h,1-6h
nsc-681101
nsc681101
1,4,7-triazacyclononane, 95%
octahydro-1h-1,4,7-triazonine
T1878
CHEMBL1650628
1h-1,4,7-triazonine, octahydro-
unii-2uif93c5h3
nsc 681101
2uif93c5h3 ,
AKOS006220515
FT-0635415
SCHEMBL132539
mfcd00012358
ITWBWJFEJCHKSN-UHFFFAOYSA-N
CS-W006212
DTXSID50197095
GS-3662
BCP06998
Q4545690
83834-39-3
AMY31179
H10640
EN300-213777
HY-W006212
PD166619
triethylenetriamine
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
saturated organic heteromonocyclic parent
crown amineCrown compounds containing only nitrogen as coordinating atom.
azacycloalkane
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID1808258Cytotoxicity against human L3.6pl cells assessed as reduction in cell growth measured after 72 hrs by CellTiter96 one aqueous solution assay2022ACS medicinal chemistry letters, Feb-10, Volume: 13, Issue:2
Development of Polyamine Lassos as Polyamine Transport Inhibitors.
AID566704Inhibition of human recombinant MMP3 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566703Inhibition of human recombinant MMP2 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566707Inhibition of mouse recombinant iNOS at 1 mM after 40 mins by colorimetric assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566705Inhibition of human recombinant MMP8 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566699Inhibition of mushroom tyrosinase at 1 mM after 10 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566706Inhibition of human recombinant MMP9 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566700Inhibition of human recombinant 5-lipoxygenase at 1 mM after 10 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566701Inhibition of recombinant anthrax lethal factor at 1 mM after 30 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566702Inhibition of human recombinant MMP1 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (75)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (6.67)18.2507
2000's23 (30.67)29.6817
2010's43 (57.33)24.3611
2020's4 (5.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.56 (24.57)
Research Supply Index4.34 (2.92)
Research Growth Index5.18 (4.65)
Search Engine Demand Index33.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other76 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]